Automated And Closed Cell Therapy Processing Systems Market Size, Share & Trends Analysis Report By Workflow (Separation, Expansion, Apheresis), By Type, By Scale, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global automated and closed cell therapy processing systems market size was valued at USD 944.8 million in 2022 and is anticipated to grow at a compound annual growth rate(CAGR) of 18.2% from 2023 to 2030. The growing popularity of regenerative medicine & cell therapies coupled with a range of benefits offered by automation technologies for the development of these therapies is expected to propel the market growth. In addition, the growing integration of software technologies and advanced therapy development processes is also anticipated to drive market growth. Furthermore, rising investments by bio manufacturers for the development of cellular therapy products through rounds of series funding are anticipated to offer lucrative growth opportunities to the market.

The global pharmaceutical business has benefited greatly from automation in cell therapy processing or manufacturing systems. The cells are chosen, isolated, modified, and expanded as part of the manufacturing process for cell therapies. In this intricate process, even a small mistake might result in incorrect cell infusion. The automated and closed cell therapy processing methods reduce the danger of the finished product. Automation in cell therapy processing lowers the risk of contamination brought on by manual labor. The size of cell operations is improved by the automated and closed cell treatment processing system by lowering the possibility of mistakes during bioprocessing.

The increasing prevalence of cancer globally has increased the demand for automated and closed-cell therapeutic processing systems. According to the Global Cancer Observatory study, 4.39 million new cases of cancer were estimated in Europe in 2020. The fully automated cell treatment processing systems are created to provide powerful processing with improved therapies for largely incurable diseases. The leading firms in the global market are contributing to the expansion by offering cutting-edge platforms for the cell therapy manufacturing process.In recent years, there has been massive growth in clinical trials associated with advanced therapies.

This growth has led to an increase in demand for advanced and automated technologies to achieve high throughput and yield. This can be attributed to the fact that automated and closed systems offer better cell handling capabilities and reduce the possibility of errors during bioprocessing.The availability of a range of systems to offer both automated integrated workflow solutions and partial automation is expected to spur the adoption rate in the space. Furthermore, the system also enables continuous monitoring of controlled therapy processing, which is being conducted for the development of new therapeutic platforms.

In addition, integrated intelligent algorithms facilitate high precision. Market players are actively engaged in the development of infrastructure to leverage the production of automated systems.For instance, in June 2021, the collaboration of Lonza and Cell Point announced its plan to utilize the Cocoon platform for the development of T-cell-based therapies. The project is being conducted to provide a proof of concept for Point-of-Care (POC) production to optimize the supply chain operations. Also, as automated systems can enhance analytical testing and facilitate quality control, the systems are expected to gain acceptance during the forecast period.

Workflow Insights

Based on workflow, the market is segmented into separation, expansion, apheresis, fill-finish, cryopreservation, and others. The expansion segment accounted for the largest revenue share of around 35.0% in 2022. The growth is majorly attributed to the presence of a substantial number of products offered under this segment. Moreover, increasing partnerships among market players for the adoption and application of systems offered under this segment are driving its growth. For instance, Angiocrine Bioscience has implemented Terumo BCT’s quantum cell expansion system to accelerate its cell therapy research.

The separation segment is expected to register the fastest CAGR during the forecast period. The cell separation process is carried out across various cellular experiments, such as molecular analysis, cellular genetic modification, production of hybridomas, and other cell research & analysis-related applications.A growing number of research activities for these applications in academic universities and other research settings is anticipated to accelerate segment growth. Apart from expansion and separation, the workflow segment comprises apheresis, fill-finish, cryopreservation, and others.

Cryopreservation and apheresis workflows are also projected to register considerable growth owing to the increasing awareness and acceptance of regenerative medicines.In February 2023, Cell and Gene Therapy Catapult, a UK-based company, announced its involvement in the development of a sizable new life science campus in Stevenage. The company has set aside over USD 900 million to build the new facility. The new campus is created to meet the high demand from the life sciences industry.

Type Insights

Based on type, the market is segmented into stem cell therapy and non-stem cell therapy. The non-stem cell therapy segment accounted for the largest revenue sharein 2022 and is anticipated to register the fastest CAGR during the forecast period. An increasing number of product launches for non-stem cell therapy applications is expected to drive segment growth. Furthermore, the success of CAR-T therapies has directed investment toward non-stem cell therapy development, thereby driving segment revenue.In February, IASO Biotherapeutics, a clinical-stage biopharmaceutical company that develops cutting-edge cell therapies, declared that the Food and Drug Administration (FDA) had granted Fast Track (FT) Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation to its new BCMA CAR-T CT103A (Equecabtagene Autoleucel) drug. Medication can be used to treat Relapsed/RefractoryMultiple Myeloma (RRMM), a severe kind of blood cancer that has ceased responding to cell treatment.

Companies are extensively engaging in partnerships and collaborations to develop new regenerative medicines for the treatment of chronic conditions. Such research projects majorly focus on applications of non-stem cells, consequently driving the non-stem cell therapy segment growth. Moreover, the growing emphasis on cell and tissue-based engineering due to massive clinical potential is also expected to accelerate the segment growth during the forecast period.The stem cell therapy segment is anticipated to witness a significant growth rate during the forecast period. Increasing awareness about therapeutic benefits offered by stem cell therapies and rising research activities associated with drug efficacy and disease understanding is expected to have a constructive impact on the growth of the stem cell therapy segment.

Scale Insights

Based on scales, the market is segmented into pre-commercial/R&D scale and commercial scale. The pre-commercial/R&D scale segment held the largest revenue share of 72.3% in 2022.At present, the market is relatively niche due to a limited number of products. Moreover, most companies are introducing their products only for research purposes. For instance, Cellares Inc., a cell therapy manufacturing company, is planning to introduce its automated cell therapy machine in 2023. Such factors are expected to drive the pre-commercial/R&D scale segment growth over the forecast period.In addition, the adoption of automated systems by research institutes due to the growing number of clinical trials for cell therapies is also projected to accelerate segment growth.

The laboratories and research institutes are witnessing a range of benefits due to the adoption of automated systems. According to a recent study published by National Center for Biotechnology Information (NCBI), automated systems assist in achieving high-speed processing and reliability of data. The commercial-scale segment is expected to register the fastest CAGR of 19.4% over the forecast period. The increasing prevalence of chronic conditions, such as cancer, is encouraging companies to develop enhanced cell-therapy-based therapeutic platforms.

Moreover, the market players are also focusing on cost optimization, thereby contributing to segment growth.In April 2022, the CITY OF HOPE, a U.S.-based cancer research and treatment facility, intended to incorporate the Curate Cell Processing System of Curate Biosciences into its workflow to generate experimental CAR-T cell immunotherapy. The company believes that using this cell, processing method will allow T-cell separation to be tackled uniquely.In February 2023, a well-known cell therapy and regenerative medicine company, Athersys Inc., announced that it has been granted a clinical Type B meeting with FDA. The company intends to strengthen its capabilities in the sophisticated MASTERS-2 clinical trials by adopting this measure.

Regional Insights

North America dominated the market and accounted for the largest revenue share of 46.1% in 2022.This high share was majorly attributed to the increased technological adoption for cell therapy processing and emphasis on high precision & production throughput. The regional market will expand further at a steady CAGR from 2023 to 2030 as the healthcare domain in the region is witnessing a significant demand for regenerative medicines. The growing investments by market players as well as research institutes are also expected to play a vital role in the region’s growth.

Europe and Asia Pacific are expected to register significant growth rates during the forecast period. A strong facility network and workforce in European countries are anticipated to fuel market growth in the region. Over the recent years, a series of fully automated platforms were introduced across European countries, which are capable of supporting the bioprocess workflows from start to end. On the other hand, the increasing government and private investments, rising healthcare needs, and establishment of accelerated approval pathways are the key driving factors for the notable growth of the market in Asia Pacific.

Key Companies & Market Share Insights

Key companies are implementing extensive strategic initiatives in the field of cell therapy automation to address the unmet needs of consumers. Technological partnerships & collaborations, mergers & acquisitions, product introductions & approvals, regional expansions, and strategic initiatives are some of the key strategies adopted by the market participants to gain higher market shares.For instance, in February 2021, Cytiva and Brooks Life Sciences agreed to extend the capabilities of the automated cold chain. The companies are working together to enhance the cryogenic cold chain capabilities of Cytiva’s automated cold chain system. Some of the prominent players operating in the global automated and closed cell therapy processing systems market include:

• MiltenyiBiotec

• Lonza

• Fresenius Kabi

• Cytiva (Danaher Corp.)

• BioSpherix, Ltd.

• Terumo Corporation

• Sartorius AG

• ThermoGenesis Holdings, Inc.

• Cellares Inc.

• Thermo Fisher Scientific, Inc.

Automated And Closed Cell Therapy Processing Systems Market Report Scope

Global Automated And Closed Cell Therapy Processing Systems Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global automated and closed cell therapy processing systems market report based on workflow, type, scale, and region:

• Workflow Outlook (Revenue, USD Million, 2018 - 2030)

  • Separation

  • Expansion

  • Apheresis

  • Fill-Finish

  • Cryopreservation

  • Others

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Stem Cell Therapy

  • Non-Stem Cell Therapy

• Scale Outlook (Revenue, USD Million, 2018 - 2030)

  • Pre-commercial/R&D Scale

  • Commercial Scale

• Regional Outlook (Revenue in USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait